Overview

* Celcuity ( CELC ) Q3 adjusted loss per share and adjusted net loss beat analyst expectations

* Company's operating expenses increased to $42.8 mln in Q3 2025

* Celcuity on track to submit NDA for gedatolisib in Q4 2025

Outlook

* Celcuity expects topline data from PIK3CA mutant cohort in late Q1 2026 or Q2 2026

* Celcuity plans to submit NDA for gedatolisib in Q4 2025

Result Drivers

* FINANCIAL STRATEGY - Convertible senior notes and term loan facility amendments strengthen capital structure

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat -$0.78 -$1.02

Adjusted (7

EPS Analysts

)

Q3 EPS -$0.92

Q3 Beat -$37.20 -$43 mln

Adjusted mln (7

Net Analysts

Income )

Q3 Net -$43.80

Income mln

Q3 $42.80

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Celcuity Inc ( CELC ) is $78.00, about 1.5% below its November 11 closing price of $79.17

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)